Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Prescient Therapeutics (PTX) unveils its new cell therapy manufacturing enhancement technology, CellPryme-M
  • CellPryme-M is a platform technology that produces superior cells which are able to withstand cancer-killing activity for a longer duration than conventional CAR-T cells
  • The company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties
  • In a show of confidence, Prescient says it will be its own first customer by using the therapy to enhance its internal programs
  • Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST

Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.

CellPryme-M is a platform technology that produces superior cells during the cell manufacturing process. These cells are said to be less prone to exhaustion, which enables it to withstand cancer-killing activity for a longer period of time, and are capable of improved tumour trafficking and penetrance, compared to the current generation of CAR-T cells.

CellPrymeM CAR-T cells were also shown to perform better than conventional CAR-T cells in highly aggressive solid cancer models, and is now ready for use in clinical studies.

Prescient said it plans to use CellPryme-M to enhance the cells used in its breakthrough OmniCAR programs.

The clinical stage oncology company will seek to license CellPryme-M to other cell therapy companies to enhance conventional CAR-T programs and enter collaborations with external parties.  

“CellPryme-M also opens up an entirely new business opportunity to license CellPryme-M to other cell therapy companies,” Prescient Managing Director and CEO Steven Yatomi-Clarke said.

“It requires minimal intervention into existing and emerging manufacturing process and therefore represents a relatively low implementation hurdle. This opens up real commercial opportunities for Prescient to incorporate CellPryme-M into third party manufacturing processes.”

“However, in a real show of confidence, Prescient will be it is own first customer by using it to enhance its internal OmniCAR programs, to combine next-gen CAR-T capabilities with superior cell phenotypes,” Steven Yatomi-Clarke said.

Shares in Prescient Therapeutics are down 9.09 per cent to $0.20 as of 12:30 pm AEST.

PTX by the numbers
More From The Market Herald

" Empire Resources (ASX:ERL) records further multi-element mineralisation at Yuinmery, WA

Empire Resources (ASX:ERL) has intersected more multi-element mineralisation at its Yuinmery project in Western Australia.

" R3D Resources (ASX:R3D) to commence drilling in QLD this weekend

R3D Resources (ASX:R3D) is gearing up to commence a drilling program at key copper and zinc…
The Market Herald Video

" DDH1 (ASX:DDH) launches share-buy back

DDH1 (ASX:DDH) has launched an on-market share buy-back program of up to 10 per cent of…
The Market Herald Video

" Lithium Australia’s (ASX:LIT) Envirostream receives first cash rebate for B-cycle scheme

Lithium Australia's (ASX:LIT) subsidiary, Envirostream Australia has received its first cash rebate for the B-cycle scheme.